Abstract

Background: Embelica officinalis Gaertn. is an Indian plant which is known for its therapeutic properties. It is especially well known as a component of the Ayuverdic medicine Triphala. This study focuses on the growth inhibitory activity of E. officinalis fruit extracts against some bacterial triggers of autoimmune inflammatory diseases, both alone and in combination with conventional antibiotics. Methods: E. officinalis fruit powder was extracted with solvents of varying polarity and screened for bacterial growth inhibition by disc diffusion assay. The minimum inhibitory concentration (MIC) was quantified by both liquid dilution and disc diffusion techniques. To screen for combinatorial effects, the E. officinalis fruit extracts were combined with a range of conventional antibiotics and tested against each bacteria using a liquid dilution assay. Toxicity was examined using Artemia nauplii and HDF bioassays. Results: The ethyl acetate E. officinalis fruit extract displayed the strongest growth inhibitory activity against all of the bacterial triggers of autoimmune inflammatory disease. This extract was a particularly potent inhibitor of P. aeruginosa growth, with an MIC values as low as 264 μg/mL.The ethyl acetate extract was also a moderate to strong growth inhibitor of P. mirabilis, K. pneumonia and A. baylyi, with MIC values generally 1000-1500 μg/mL. The methanolic and aqueous extracts also inhibited the growth of all bacteria, although generally with only moderate to low activity. Whilst no synergistic interactions were detected in combinations containing the E. officinalis fruit extracts and conventional antibiotics, a number of combinations produced additive effects. These combinations are beneficial as they provide enhanced antibacterial efficacy compared to treatment with the antibiotic or extract components alone. No antagonistic interactions were detected. Therefore, use of the extracts in combination with conventional antibiotics would not compromise the antibiotics efficacy. All extracts were nontoxic in the Artemia nauplii and HDF toxicity assays, further indicating their potential for medicinal use. Conclusion: The E. officinalis fruit extracts were moderate inhibitors of the bacterial triggers of selected autoimmune inflammatory diseases. Furthermore, the extracts potentiated the activity of chloramphenicol and tetracycline against otherwise resistant bacterial strains. Isolation of the active compounds and the potentiating agents may be beneficial in antibiotic drug design.

Highlights

  • The incorrect and over use of antibiotics has resulted in a dramatic rise in the prevalence of antibiotic resistant bacterial pathogens and several extremely (XDR) or totally drug resistant (TDR) pathogens have recently been reported.[1]

  • This study focuses on the growth inhibitory activity of E. officinalis fruit extracts against some bacterial triggers of autoimmune inflammatory diseases, both alone and in combination with conventional antibiotics

  • This study investigated the ability of E. officinalis fruit extracts to inhibit the growth of some bacterial triggers of autoimmune inflammatory diseases, both alone and in combination with conventional antibiotics

Read more

Summary

Introduction

The incorrect and over use of antibiotics has resulted in a dramatic rise in the prevalence of antibiotic resistant bacterial pathogens and several extremely (XDR) or totally drug resistant (TDR) pathogens have recently been reported.[1]. This study focuses on the growth inhibitory activity of E. officinalis fruit extracts against some bacterial triggers of autoimmune inflammatory diseases, both alone and in combination with conventional antibiotics. Results: The ethyl acetate E. officinalis fruit extract displayed the strongest growth inhibitory activity against all of the bacterial triggers of autoimmune inflammatory disease. This extract was a potent inhibitor of P. aeruginosa growth, with an MIC values as low as 264 μg/mL.

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.